Ovarian cancer biomarkers: current state and future implications from high-throughput technologies

Area of Science:

• Gynecologic Oncology
• Biomarker Discovery
• Translational Medicine

Background:

• Ovarian cancer is the leading cause of gynecological cancer death globally, with stagnant survival rates.
• Despite extensive research, few novel serum biomarkers have been approved beyond carbohydrate antigen 125 (CA-125).
• Past biomarker discovery efforts were hampered by poor study design and bias, leading to unreliable results.

Purpose of the Study:

• To review the current status of ovarian cancer biomarker research, focusing on diagnostic serum markers.
• To examine established guidelines for assessing biomarker clinical utility.
• To explore emerging high-throughput technologies for novel biomarker identification.

Main Methods:

• Review of existing literature on ovarian cancer biomarkers.
• Analysis of clinical utility assessment guidelines for biomarkers.
• Discussion of high-throughput technologies like targeted sequencing and proteomics.

Main Results:

• Limited success in identifying clinically relevant ovarian cancer biomarkers to date.
• Recognition of the need for improved study design and bias mitigation.
• Emerging technologies offer new avenues for biomarker discovery.

Conclusions:

• Improved understanding of biomarker development phases and guidelines is crucial to avoid past pitfalls.
• High-throughput technologies are revitalizing the search for effective ovarian cancer diagnostic serum markers.
• Continued research focusing on robust methodologies is essential for advancing ovarian cancer diagnostics.